USANA Health Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock and Earnings Per Share

Common Stock and Earnings Per Share

9 Months Ended

Sep. 28, 2024

COMMON STOCK AND EARNINGS PER SHARE

Basic earnings per share (“EPS”) is based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic EPS based on the time they were outstanding in any period. Diluted EPS is based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted EPS calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated:


	Three Months Ended				Nine Months Ended
	September 28, 2024		September 30, 2023		September 28, 2024		September 30, 2023
Net earnings available to common shareholders	$	10,607	$	11,347	$	37,576	$	47,022
Weighted average common shares outstanding - basic	19,078		19,245		19,108		19,283
Dilutive effect of in-the-money equity awards	5		127		73		93
Weighted average common shares outstanding - diluted	19,083		19,372		19,181		19,376
Earnings per common share from net earnings - basic	$	0.56	$	0.59	$	1.97	$	2.44
Earnings per common share from net earnings - diluted	$	0.56	$	0.59	$	1.96	$	2.43

Equity awards excluded as the impact was anti-dilutive	628		315		570		322

There were no shares repurchased during the three months ended September 28, 2024. During the three months ended September 30, 2023, the Company repurchased and retired 180 shares for $11,657, inclusive of accrued excise tax of $58. During the nine months ended September 28, 2024 and September 30, 2023, the Company repurchased and retired 194 and 180 shares for $9,483 and $11,657, inclusive of accrued excise tax of $39 and $58 respectively, under the Company's share repurchase plan.

The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

As of September 28, 2024, the remaining authorized repurchase amount under the stock repurchase plan was $61,703, inclusive of accrued excise tax. There is no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.